dpDARSH PHARMALINKREGULATORY CONSULTANCY
← Knowledge Hub

CASE STUDY / CMC & LIFECYCLE

Sequencing a manufacturing and testing transfer

A transfer programme needed a filing strategy that accounted for testing-equipment constraints.

Staged filingTechnical constraints made explicit

An anonymised example from the principal consultant’s prior career experience, not a Darsh Pharmalink client engagement. Product and organisation names are withheld.

The challenge

Manufacturing, packaging and dissolution-testing changes could not all be implemented on the same technical timeline.

The approach

Developed a staged Type II variation strategy, separating site and packaging changes from a later dissolution-testing transfer. Included an external laboratory in the approach to address equipment constraints.

The documented output

A staged regulatory strategy that aligned the proposed change sequence with the technical dependencies.

What this illustrates

A single operational programme may need more than one regulatory step. Assessing the dependencies early creates a more realistic implementation plan.

This example illustrates a regulatory approach in a specific assignment. It does not predict outcomes for other products or jurisdictions.

Discuss a similar challenge →

A CLEAR NEXT STEP

Contact our
experts today.

Discuss your requirements →